Aurinia Pharmaceuticals Management
Management criteria checks 2/4
Aurinia Pharmaceuticals' CEO is Peter Greenleaf, appointed in Apr 2019, has a tenure of 6.08 years. total yearly compensation is $6.42M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.49% of the company’s shares, worth $5.44M. The average tenure of the management team and the board of directors is 5.1 years and 1.8 years respectively.
Key information
Peter Greenleaf
Chief executive officer
US$6.4m
Total compensation
| CEO salary percentage | 12.82% |
| CEO tenure | 6.1yrs |
| CEO ownership | 0.5% |
| Management average tenure | 5.1yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality
May 19
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 15Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 09
Academic Medical Centers Will Expand Lupus Care Opportunities
Expansion into medical centers and new treatment guidelines may drive higher prescriber engagement and revenue for LUPKYNIS.Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth
Apr 26Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues
Apr 01Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Mar 02Aurinia Pharmaceuticals: There's Still Time For Sales Growth
Feb 21Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25%
Dec 11Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon
Nov 08Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Sep 06Aurinia Pharmaceuticals Appears Undervalued
Jul 05We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
May 24Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report
May 05Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
May 02Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | US$40m |
| Dec 31 2024 | US$6m | US$823k | US$6m |
| Sep 30 2024 | n/a | n/a | -US$23m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$11m | US$823k | -US$78m |
| Sep 30 2023 | n/a | n/a | -US$77m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$97m |
| Dec 31 2022 | US$9m | US$791k | -US$108m |
| Sep 30 2022 | n/a | n/a | -US$115m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$168m |
| Dec 31 2021 | US$1m | US$724k | -US$181m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$148m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$11m | US$673k | -US$103m |
| Sep 30 2020 | n/a | n/a | -US$129m |
| Jun 30 2020 | n/a | n/a | -US$110m |
| Mar 31 2020 | n/a | n/a | -US$102m |
| Dec 31 2019 | US$5m | US$438k | -US$88m |
Compensation vs Market: Peter's total compensation ($USD6.42M) is above average for companies of similar size in the US market ($USD3.98M).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
CEO
Peter Greenleaf (54 yo)
Mr. Peter S. Greenleaf, M.B.A., has been Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. since April 29, 2019 and serves as its President. He was President of Aurinia Pharmaceuticals I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$6.42m | 0.49% $ 5.4m | |
| Chief Financial Officer | 5.1yrs | US$2.30m | 0.17% $ 1.9m | |
| Chief Operations Officer | no data | US$2.51m | 0.22% $ 2.4m | |
| Executive VP | 4.5yrs | US$2.22m | 0.13% $ 1.4m | |
| Chief Medical Officer | no data | US$1.33m | 0.0078% $ 85.7k | |
| Executive Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior Vice President of Manufacturing & Supply Chain | no data | no data | no data |
Experienced Management: AUPH's management team is seasoned and experienced (5.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.1yrs | US$6.42m | 0.49% $ 5.4m | |
| Independent Director | no data | no data | no data | |
| Independent Chairman | less than a year | no data | no data | |
| Director | 5.5yrs | US$270.00k | 0.0096% $ 105.3k | |
| Independent Director | less than a year | US$346.72k | no data | |
| Independent Director | 1.8yrs | US$264.49k | 0.0099% $ 108.9k | |
| Director | 1.8yrs | US$256.99k | 0.0094% $ 103.3k | |
| Director | 10yrs | US$251.33k | 0.033% $ 361.6k | |
| Independent Director | no data | no data | no data |
Experienced Board: AUPH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/28 14:02 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aurinia Pharmaceuticals Inc. is covered by 22 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Dae Gon Ha | BTIG |
| Neil Maruoka | Canaccord Genuity |